Angina Pectoris Drugs Market Report 2026

Angina Pectoris Drugs Market Overview

• Angina Pectoris Drugs market size has reached to $12.88 billion in 2025 • Expected to grow to $17.67 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pectoris Drug Market • Market Trend: Hikma Pharmaceuticals Unveils Labetalol Hydrochloride Injection, Usp, Marking A Milestone In Angina Pectoris Drug Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Angina Pectoris Drugs Market?

Angina pectoris drugs are medications used to treat angina pectoris, a medical illness that causes chest pain or discomfort when a portion of the heart does not receive enough blood and oxygen. Angina pectoris drugs treat chest pain or discomfort due to coronary heart disease. The main drugs of angina pectoris drugs are nitrates, antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other drugs. Nitrates and nitrites are nitrogen and oxygen atom-containing chemicals. Nitrates are frequently used to treat angina pectoris, a condition that involves chest pain or discomfort caused by decreased blood supply to the heart. The indications include stable angina, unstable angina, and prinzmetal’s angina. The angina pectoris drugs are administered via oral, parenteral, transdermal, other route of administrations that are used by hospitals, homecare, specialty clinics, other end users.

What Is The Angina Pectoris Drugs Market Growth Forecast?

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $17.67 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in precision medicine, growth of wearable cardiac monitoring devices, rising demand for combination therapies, increased investment in r&d for anti-ischemic agents, telehealth integration in cardiac care. Major trends in the forecast period include personalized angina management, minimally invasive drug delivery systems, fixed-dose combination therapies, growing geriatric patient population, telemedicine and remote cardiac monitoring.

Global Angina Pectoris Drugs Market Segmentation

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins 2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina 3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates 2) By Antiplatelet Agents: Aspirin, Clopidogrel 3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers 4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers 5) By Anti-Ischemic Agents: Ranolazine, Ivabradine 6) By Statins: Atorvastatin, Rosuvastatin

What Are The Drivers Of The Angina Pectoris Drugs Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the angina pectoris drug market going forward. Cardiovascular diseases encompass a range of disorders that impact the heart and blood vessels, including conditions like coronary artery disease, high blood pressure, heart failure, and stroke. The increasing prevalence of cardiovascular diseases (CVD) can be attributed to several factors, including an aging population, unhealthy lifestyles, and the obesity epidemic. Angina pectoris medications, such as nitrates, beta-blockers, and calcium channel blockers, effectively relieve chest pain and discomfort caused by insufficient blood flow to the heart, thereby enhancing patients' overall quality of life. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the angina pectoris drug industry. The increasing rates of diabetes are expected to propel the growth of the angina pectoris drug market in the coming years. Hypertension, sometimes known as high blood pressure, is a medical disorder characterized by excessive arterial blood pressure. Diabetes is a long-term medical disorder marked by high blood glucose (sugar) levels. Diabetes and hypertension are prevalent risk factors for cardiovascular conditions, such as angina pectoris. The rising prevalence of these illnesses increases the demand for angina medicines. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore. The increasing rates of diabetes are driving the angina pectoris drug industry.

Key Players In The Global Angina Pectoris Drugs Market

Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S

Global Angina Pectoris Drugs Market Trends and Insights

Major companies operating in the angina pectoris drug market are focusing on adopting new technologies to sustain their position in the market, such as the U.S. Food and Drug Administration's approval of Labetalol Hydrochloride Injection for treating angina and to better meet the needs of their existing consumers. Nitrostat (Nitroglycerin Sublingual Tablets) has been authorized by the United States Food and Drug Administration (FDA) for the immediate treatment of angina pectoris or the acute prevention of angina pectoris. For instance, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. The Food and Drug Administration of the United States has authorized this product. In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.

Regional Insights

North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Angina Pectoris Drugs Market?

The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Angina Pectoris Drugs Market Report 2026?

The angina pectoris drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.